The Companion Diagnostics (CDx) Market 2014-2024

The Companion Diagnostics (CDx) MarketThe Companion Diagnostics (CDx) Market 2014-2024 PR Newswire LONDON, January 9, 2014 Our new study shows you the commercial potential of companion diagnostics What does the future hold for the companion diagnostics market? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 145 page report provides 103 tables, figures and charts. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, interviews, trends, opportunities, and revenue predictions. Forecasts from 2014-2024 and other analyses show you commercial prospects Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read full transcripts of two exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales: - Biomonitor A/S, Arsalan Kharazmi, PhD, CEO - Ambry Genetics, Ardy Arianpour, MBA, Senior Vice President of Business Development You will find prospects for key submarkets Growth in this market will be fuelled by an increasing demand for safer and more efficacious medicines.